Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis

Hitoshi Niikura, Toshimitsu Koizumi, Kiyoshi Ito, Kunihiro Okamura, Nobuo Yaegashi

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


We report on three cases of long-term dialysis patients with gynecological malignancies who were successfully treated with chemotherapy. Two epithelial ovarian carcinoma patients were treated with a single agent, carboplatin (100-200 mg/m2). One recurrent endometrial carcinoma patient was treated with carboplatin (200 mg/m2) and paclitaxel (135 mg/m 2). Hemodialysis was started 2 h after the carboplatin infusion and lasted 4 h in all three cases. All patients tolerated these therapies without significant myelosuppression or severe side-effects. Our findings suggest these regimens are feasible, and the combination of paclitaxel and carboplatin is effective chemotherapy when administered to long-term hemodialysis patients with recurrent endometrial carcinoma.

Original languageEnglish
Pages (from-to)735-738
Number of pages4
JournalAnti-cancer drugs
Issue number9
Publication statusPublished - 2003 Oct


  • Carboplatin
  • Endometrial carcinoma
  • Hemodialysis
  • Ovarian carcinoma
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis'. Together they form a unique fingerprint.

Cite this